Angiodynamics (ANGO) Receivables (2011 - 2026)

Angiodynamics' Receivables history runs 16 years deep, the most recent figure standing at $48.3 million for Q2 2026.

• Quarterly Receivables rose 12.67% year-over-year to $48.3 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $48.3 million (up 12.67% YoY) and the FY2026 annual result came in at $48.3 million, up 12.67% from the prior year.
• Receivables was $48.3 million for Q2 2026 at Angiodynamics, up from $45.6 million in the prior quarter.
• Across five years, Receivables topped out at $53.6 million in Q3 2022 and bottomed at $39.6 million in Q3 2024.
• A 5-year average of $47.2 million and a median of $46.9 million in 2026 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables soared 51.3% — and 2024, when it slipped 20.48%.
• Angiodynamics' Receivables stood at $52.9 million in 2022, then fell by 2.36% to $51.6 million in 2023, then decreased by 16.37% to $43.2 million in 2024, then grew by 2.96% to $44.4 million in 2025, then advanced by 8.76% to $48.3 million in 2026.
• Business Quant data shows ANGO's Receivables at $48.3 million in Q2 2026, $45.6 million in Q1 2026, and $44.4 million in Q4 2025.